Last 12 months
Inside the activity.
1 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 7, 2023 18:04 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 2,455 | $35.01 | $85,949.55 |
DisclosureSEC source: 0001628908-23-000045 · wf-form4_167823026516991.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,123 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2022. F4 · shares: This number represents shares of Class A Common Stock sold to satisfy the tax withholding obligation due upon vesting of LSUs. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.975 to $35.060, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 18:04 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 87,901 | $34.40 | $3,023,794.40 |
DisclosureSEC source: 0001628908-23-000045 · wf-form4_167823026516991.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,578 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2022. F4 · shares: This number represents shares of Class A Common Stock sold to satisfy the tax withholding obligation due upon vesting of LSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.95 to $34.93, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 23:06 UTC |
Blackley SethDirector · Chief Executive Officer
|
SaleClass A Common Stock | 2,012 | $35.01 | $70,440.12 |
DisclosureSEC source: 0001628908-23-000047 · wf-form4_167823038064797.xml · nonDerivative · entry 3 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,066 F3 · shares: This number represents shares of Class A Common Stock sold to satisfy the tax withholding obligation due upon vesting of LSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.975 to $35.060, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 23:06 UTC |
Blackley SethDirector · Chief Executive Officer
|
SaleClass A Common Stock | 71,916 | $34.40 | $2,473,910.40 |
DisclosureSEC source: 0001628908-23-000047 · wf-form4_167823038064797.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,078 F3 · shares: This number represents shares of Class A Common Stock sold to satisfy the tax withholding obligation due upon vesting of LSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.95 to $34.93, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 18:04 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionLeveraged Restricted Stock Unit · Derivative | 400,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000045 · wf-form4_167823026516991.xml · derivative · entry 6 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 400,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: LSUs vested on March 3, 2023. F10 · derivative.expiration_date: These LSUs do not expire. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 18:04 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000045 · wf-form4_167823026516991.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of the leveraged stock units ("LSUs") granted to Mr. Williams on March 2, 2020, based on the cumulative performance of the Issuer's Class A Common Stock. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:06 UTC |
Blackley SethDirector · Chief Executive Officer
|
Exercise / conversionLeveraged Restricted Stock Unit · Derivative | 360,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000047 · wf-form4_167823038064797.xml · derivative · entry 5 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 360,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: LSUs vested on March 3, 2023. F8 · derivative.expiration_date: These LSUs do not expire. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:06 UTC |
Blackley SethDirector · Chief Executive Officer
|
Exercise / conversionClass A Common Stock | 360,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000047 · wf-form4_167823038064797.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of the leveraged stock units ("LSUs") granted to Mr. Blackley on March 2, 2020, based on the cumulative performance of the Issuer's Class A Common Stock. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:35 UTC |
Weinberg JonathanGeneral Counsel
|
Tax withholdingClass A Common Stock | 3,330 | $35.15 | $117,049.50 |
DisclosureSEC source: 0001628908-23-000037 · wf-form4_167788290033047.xml · nonDerivative · entry 3 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,969 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:42 UTC |
Tutewohl SteveChief Operating Officer
|
Tax withholdingClass A Common Stock | 3,200 | $35.15 | $112,480.00 |
DisclosureSEC source: 0001628908-23-000041 · wf-form4_167788327939137.xml · nonDerivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,331 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:37 UTC |
Johnson John PaulChief Financial Officer
|
Tax withholdingClass A Common Stock | 9,020 | $35.15 | $317,053.00 |
DisclosureSEC source: 0001628908-23-000039 · wf-form4_167788304937171.xml · nonDerivative · entry 3 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,016 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:28 UTC |
McCarthy Daniel JosephPRESIDENT
|
Tax withholdingClass A Common Stock | 4,687 | $35.15 | $164,748.05 |
DisclosureSEC source: 0001628908-23-000033 · wf-form4_167788250778505.xml · nonDerivative · entry 3 McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,333 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 3 previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:07 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Option (right to buy) · Derivative | 100,940 | $0.00 Strike: $6.87 | $0.00 |
DisclosureSEC source: 0001628908-23-000031 · wf-form4_167779485157324.xml · derivative · entry 7 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,060 Underlying: Class A Common Stock · 100,940 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F7 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2018. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:07 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 9,060 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-23-000031 · wf-form4_167779485157324.xml · derivative · entry 6 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,060 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2017. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:07 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 100,940 | $34.98 | $3,530,881.20 |
DisclosureSEC source: 0001628908-23-000031 · wf-form4_167779485157324.xml · nonDerivative · entry 4 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,479 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.57 to $35.27, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:07 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 100,940 | $6.87 | $693,457.80 |
DisclosureSEC source: 0001628908-23-000031 · wf-form4_167779485157324.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:07 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 9,060 | $34.97 | $316,828.20 |
DisclosureSEC source: 0001628908-23-000031 · wf-form4_167779485157324.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,479 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.620 to $35.265, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:07 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 9,060 | $3.84 | $34,790.40 |
DisclosureSEC source: 0001628908-23-000031 · wf-form4_167779485157324.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:32 UTC |
Shams AammaadChief Accounting Officer
|
Tax withholdingClass A Common Stock | 672 | $35.26 | $23,694.72 |
DisclosureSEC source: 0001628908-23-000035 · wf-form4_167788271090386.xml · nonDerivative · entry 2 Shams Aammaad · CIK 0001815354 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,212 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:32 UTC |
Shams AammaadChief Accounting Officer
|
GrantClass A Common Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000035 · wf-form4_167788271090386.xml · nonDerivative · entry 1 Shams Aammaad · CIK 0001815354 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,884 F1 · security: Represents restricted stock units granted to Mr. Shams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2024, and 33% on March 1, 2025, and March 1, 2026. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:35 UTC |
Weinberg JonathanGeneral Counsel
|
Tax withholdingClass A Common Stock | 2,265 | $35.26 | $79,863.90 |
DisclosureSEC source: 0001628908-23-000037 · wf-form4_167788290033047.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,299 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:35 UTC |
Weinberg JonathanGeneral Counsel
|
GrantClass A Common Stock | 12,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000037 · wf-form4_167788290033047.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,564 F1 · security: Represents restricted stock units granted to Mr. Weinberg pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2024, and 33% on March 1, 2025, and March 1, 2026. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:44 UTC |
Blackley SethDirector · Chief Executive Officer
|
Tax withholdingClass A Common Stock | 7,470 | $35.26 | $263,392.20 |
DisclosureSEC source: 0001628908-23-000043 · wf-form4_167788347302001.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,994 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:44 UTC |
Blackley SethDirector · Chief Executive Officer
|
GrantClass A Common Stock | 59,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000043 · wf-form4_167788347302001.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,464 F1 · security: Represents restricted stock units granted to Mr. Blackley pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2024, and 33% on March 1, 2025, and March 1, 2026. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:42 UTC |
Tutewohl SteveChief Operating Officer
|
Tax withholdingClass A Common Stock | 2,176 | $35.26 | $76,725.76 |
DisclosureSEC source: 0001628908-23-000041 · wf-form4_167788327939137.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,531 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:42 UTC |
Tutewohl SteveChief Operating Officer
|
GrantClass A Common Stock | 17,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000041 · wf-form4_167788327939137.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,707 F1 · security: Represents restricted stock units granted to Mr. Tutewohl pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2024, and 33% on March 1, 2025, and March 1, 2026. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:37 UTC |
Johnson John PaulChief Financial Officer
|
Tax withholdingClass A Common Stock | 3,681 | $35.26 | $129,792.06 |
DisclosureSEC source: 0001628908-23-000039 · wf-form4_167788304937171.xml · nonDerivative · entry 2 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,036 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:37 UTC |
Johnson John PaulChief Financial Officer
|
GrantClass A Common Stock | 20,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000039 · wf-form4_167788304937171.xml · nonDerivative · entry 1 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,717 F1 · security: Represents restricted stock units granted to Mr. Johnson pursuant to the Evolent Health, Inc. Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2024, and 33% on March 1, 2025, and March 1, 2026. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:28 UTC |
McCarthy Daniel JosephPRESIDENT
|
Tax withholdingClass A Common Stock | 2,457 | $35.26 | $86,633.82 |
DisclosureSEC source: 0001628908-23-000033 · wf-form4_167788250778505.xml · nonDerivative · entry 2 McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,020 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 3 previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:28 UTC |
McCarthy Daniel JosephPRESIDENT
|
GrantClass A Common Stock | 27,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000033 · wf-form4_167788250778505.xml · nonDerivative · entry 1 McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,477 F1 · security: Represents restricted stock units granted to Mr. McCarthy pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2024, and 33% on March 1, 2025, and March 1, 2026. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 3 previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:19 UTC |
Weinberg JonathanGeneral Counsel
|
Tax withholdingClass A Common Stock | 3,847 | $28.08 | $108,023.76 |
DisclosureSEC source: 0001628908-23-000025 · wf-form4_167719798173380.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,806 F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of PSUs. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:19 UTC |
Weinberg JonathanGeneral Counsel
|
GrantClass A Common Stock | 11,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000025 · wf-form4_167719798173380.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,653 F1 · shares: Represents the number of shares received upon the settlement of the first tranche of performance-based share units (PSUs) awarded to the reporting person on March 1, 2021, following the certification of achievement of specified performance metrics. The shares underlying the first tranche of the PSU award vested at the conclusion of the performance period on December 31, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:16 UTC |
Johnson John PaulChief Financial Officer
|
Tax withholdingClass A Common Stock | 20,025 | $28.08 | $562,302.00 |
DisclosureSEC source: 0001628908-23-000023 · wf-form4_167719779801664.xml · nonDerivative · entry 2 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,304 F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of PSUs. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:16 UTC |
Johnson John PaulChief Financial Officer
|
GrantClass A Common Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000023 · wf-form4_167719779801664.xml · nonDerivative · entry 1 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,329 F1 · shares: Represents the number of shares received upon the settlement of the first tranche of performance-based share units (PSUs) awarded to the reporting person on March 1, 2021, following the certification of achievement of specified performance metrics. The shares underlying the first tranche of the PSU award vested at the conclusion of the performance period on December 31, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:10 UTC |
Tutewohl SteveChief Operating Officer
|
Tax withholdingClass A Common Stock | 4,774 | $28.08 | $134,053.92 |
DisclosureSEC source: 0001628908-23-000021 · wf-form4_167719742371751.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,696 F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of PSUs. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:10 UTC |
Tutewohl SteveChief Operating Officer
|
GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000021 · wf-form4_167719742371751.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,470 F1 · shares: Represents the number of shares received upon the settlement of the first tranche of performance-based share units (PSUs) awarded to the reporting person on March 1, 2021, following the certification of achievement of specified performance metrics. The shares underlying the first tranche of the PSU award vested at the conclusion of the performance period on December 31, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:59 UTC |
McCarthy Daniel JosephPRESIDENT
|
Tax withholdingClass A Common Stock | 8,461 | $28.08 | $237,584.88 |
DisclosureSEC source: 0001628908-23-000019 · wf-form4_167719674581200.xml · nonDerivative · entry 2 McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,920 F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of PSUs. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of a Form 3 previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:59 UTC |
McCarthy Daniel JosephPRESIDENT
|
GrantClass A Common Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000019 · wf-form4_167719674581200.xml · nonDerivative · entry 1 McCarthy Daniel Joseph · CIK 0001946147 · PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,381 F1 · shares: Represents the number of shares received upon the settlement of the first tranche of performance-based share units (PSUs) awarded to the reporting person on March 1, 2021, following the certification of achievement of specified performance metrics. The shares underlying the first tranche of the PSU award vested at the conclusion of the performance period on December 31, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of a Form 3 previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:52 UTC |
Blackley SethDirector · Chief Executive Officer
|
Tax withholdingClass A Common Stock | 87,786 | $28.08 | $2,465,030.88 |
DisclosureSEC source: 0001628908-23-000017 · wf-form4_167719632820675.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,462 F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of PSUs. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:52 UTC |
Blackley SethDirector · Chief Executive Officer
|
GrantClass A Common Stock | 206,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-23-000017 · wf-form4_167719632820675.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,248 F1 · shares: Represents the number of shares received upon the settlement of the first tranche of performance-based share units (PSUs) awarded to the reporting person on March 1, 2021, following the certification of achievement of specified performance metrics. The shares underlying the first tranche of the PSU award vested at the conclusion of the performance period on December 31, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:05 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-23-000007 · wf-form4_167546189100613.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,060 Underlying: Class A Common Stock · 110,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2017. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:05 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 1,500 | $32.66 | $48,990.00 |
DisclosureSEC source: 0001628908-23-000007 · wf-form4_167546189100613.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,479 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.630 to $32.740, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:05 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 108,500 | $32.15 | $3,488,275.00 |
DisclosureSEC source: 0001628908-23-000007 · wf-form4_167546189100613.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,979 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.630 to $32.625, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:05 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 110,000 | $3.84 | $422,400.00 |
DisclosureSEC source: 0001628908-23-000007 · wf-form4_167546189100613.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 736,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:58 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-23-000002 · wf-form4_167295586188308.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,060 Underlying: Class A Common Stock · 110,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2016 and December 1, 2017. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:58 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 3,292 | $28.18 | $92,768.56 |
DisclosureSEC source: 0001628908-23-000002 · wf-form4_167295586188308.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,479 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.83 to $28.47, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:58 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 106,708 | $27.12 | $2,893,920.96 |
DisclosureSEC source: 0001628908-23-000002 · wf-form4_167295586188308.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,771 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.82 to $27.80, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:58 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 110,000 | $3.84 | $422,400.00 |
DisclosureSEC source: 0001628908-23-000002 · wf-form4_167295586188308.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 736,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:58 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-22-000158 · wf-form4_167027751161266.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,060 Underlying: Class A Common Stock · 110,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2016. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:58 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 900 | $29.09 | $26,181.00 |
DisclosureSEC source: 0001628908-22-000158 · wf-form4_167027751161266.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,479 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.070 to $29.180, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.